Clinical features and outcomes of COVID-19 admissions in a population with a high prevalence of HIV and tuberculosis : a multicentre cohort study
© 2022. The Author(s)..
BACKGROUND: There is still a paucity of evidence on the outcomes of coronavirus disease 2019 (COVID-19) among people living with human immunodeficiency virus (PWH) and those co-infected with tuberculosis (TB), particularly in areas where these conditions are common. We describe the clinical features, laboratory findings and outcome of hospitalised PWH and human immunodeficiency virus (HIV)-uninfected COVID-19 patients as well as those co-infected with tuberculosis (TB).
METHODS: We conducted a multicentre cohort study across three hospitals in Cape Town, South Africa. All adults requiring hospitalisation with confirmed COVID-19 pneumonia from March to July 2020 were analysed.
RESULTS: PWH comprised 270 (19%) of 1434 admissions. There were 47 patients with active tuberculosis (3.3%), of whom 29 (62%) were PWH. Three-hundred and seventy-three patients (26%) died. The mortality in PWH (n = 71, 26%) and HIV-uninfected patients (n = 296, 25%) was comparable. In patients with TB, PWH had a higher mortality than HIV-uninfected patients (n = 11, 38% vs n = 3, 20%; p = 0.001). In multivariable survival analysis a higher risk of death was associated with older age (Adjusted Hazard Ratio (AHR) 1.03 95%CI 1.02-1.03, p < 0.001), male sex (AHR1.38 (95%CI 1.12-1.72, p = 0.003) and being "overweight or obese" (AHR 1.30 95%CI 1.03-1.61 p = 0.024). HIV (AHR 1.28 95%CI 0.95-1.72, p 0.11) and active TB (AHR 1.50 95%CI 0.84-2.67, p = 0.17) were not independently associated with increased risk of COVID-19 death. Risk factors for inpatient mortality in PWH included CD4 cell count < 200 cells/mm3, higher admission oxygen requirements, absolute white cell counts, neutrophil/lymphocyte ratios, C-reactive protein, and creatinine levels.
CONCLUSION: In a population with high prevalence of HIV and TB, being overweight/obese was associated with increased risk of mortality in COVID-19 hospital admissions, emphasising the need for public health interventions in this patient population.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
BMC infectious diseases - 22(2022), 1 vom: 20. Juni, Seite 559 |
Sprache: |
Englisch |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Completed 22.06.2022 Date Revised 02.11.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12879-022-07519-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM342466194 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM342466194 | ||
003 | DE-627 | ||
005 | 20231226014159.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12879-022-07519-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1141.xml |
035 | |a (DE-627)NLM342466194 | ||
035 | |a (NLM)35725387 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Parker, Arifa |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical features and outcomes of COVID-19 admissions in a population with a high prevalence of HIV and tuberculosis |b a multicentre cohort study |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.06.2022 | ||
500 | |a Date Revised 02.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a BACKGROUND: There is still a paucity of evidence on the outcomes of coronavirus disease 2019 (COVID-19) among people living with human immunodeficiency virus (PWH) and those co-infected with tuberculosis (TB), particularly in areas where these conditions are common. We describe the clinical features, laboratory findings and outcome of hospitalised PWH and human immunodeficiency virus (HIV)-uninfected COVID-19 patients as well as those co-infected with tuberculosis (TB) | ||
520 | |a METHODS: We conducted a multicentre cohort study across three hospitals in Cape Town, South Africa. All adults requiring hospitalisation with confirmed COVID-19 pneumonia from March to July 2020 were analysed | ||
520 | |a RESULTS: PWH comprised 270 (19%) of 1434 admissions. There were 47 patients with active tuberculosis (3.3%), of whom 29 (62%) were PWH. Three-hundred and seventy-three patients (26%) died. The mortality in PWH (n = 71, 26%) and HIV-uninfected patients (n = 296, 25%) was comparable. In patients with TB, PWH had a higher mortality than HIV-uninfected patients (n = 11, 38% vs n = 3, 20%; p = 0.001). In multivariable survival analysis a higher risk of death was associated with older age (Adjusted Hazard Ratio (AHR) 1.03 95%CI 1.02-1.03, p < 0.001), male sex (AHR1.38 (95%CI 1.12-1.72, p = 0.003) and being "overweight or obese" (AHR 1.30 95%CI 1.03-1.61 p = 0.024). HIV (AHR 1.28 95%CI 0.95-1.72, p 0.11) and active TB (AHR 1.50 95%CI 0.84-2.67, p = 0.17) were not independently associated with increased risk of COVID-19 death. Risk factors for inpatient mortality in PWH included CD4 cell count < 200 cells/mm3, higher admission oxygen requirements, absolute white cell counts, neutrophil/lymphocyte ratios, C-reactive protein, and creatinine levels | ||
520 | |a CONCLUSION: In a population with high prevalence of HIV and TB, being overweight/obese was associated with increased risk of mortality in COVID-19 hospital admissions, emphasising the need for public health interventions in this patient population | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a HIV | |
650 | 4 | |a Obesity | |
650 | 4 | |a Tuberculosis | |
700 | 1 | |a Boloko, Linda |e verfasserin |4 aut | |
700 | 1 | |a Moolla, Muhammad S |e verfasserin |4 aut | |
700 | 1 | |a Ebrahim, Nabilah |e verfasserin |4 aut | |
700 | 1 | |a Ayele, Birhanu T |e verfasserin |4 aut | |
700 | 1 | |a Broadhurst, Alistair G B |e verfasserin |4 aut | |
700 | 1 | |a Mashigo, Boitumelo |e verfasserin |4 aut | |
700 | 1 | |a Titus, Gideon |e verfasserin |4 aut | |
700 | 1 | |a de Wet, Timothy |e verfasserin |4 aut | |
700 | 1 | |a Boliter, Nicholas |e verfasserin |4 aut | |
700 | 1 | |a Rosslee, Michael-Jon |e verfasserin |4 aut | |
700 | 1 | |a Papavarnavas, Nectarios |e verfasserin |4 aut | |
700 | 1 | |a Abrahams, Riezaah |e verfasserin |4 aut | |
700 | 1 | |a Mendelson, Marc |e verfasserin |4 aut | |
700 | 1 | |a Dlamini, Sipho |e verfasserin |4 aut | |
700 | 1 | |a Taljaard, Jantjie J |e verfasserin |4 aut | |
700 | 1 | |a Prozesky, Hans W |e verfasserin |4 aut | |
700 | 1 | |a Mowlana, Abdurasiet |e verfasserin |4 aut | |
700 | 1 | |a Viljoen, Abraham J |e verfasserin |4 aut | |
700 | 1 | |a Schrueder, Neshaad |e verfasserin |4 aut | |
700 | 1 | |a Allwood, Brian W |e verfasserin |4 aut | |
700 | 1 | |a Lalla, Usha |e verfasserin |4 aut | |
700 | 1 | |a Dave, Joel A |e verfasserin |4 aut | |
700 | 1 | |a Calligaro, Greg |e verfasserin |4 aut | |
700 | 1 | |a Levin, Dion |e verfasserin |4 aut | |
700 | 1 | |a Maughan, Deborah |e verfasserin |4 aut | |
700 | 1 | |a Ntusi, Ntobeko A B |e verfasserin |4 aut | |
700 | 1 | |a Nyasulu, Peter S |e verfasserin |4 aut | |
700 | 1 | |a Meintjes, Graeme |e verfasserin |4 aut | |
700 | 1 | |a Koegelenberg, Coenraad F N |e verfasserin |4 aut | |
700 | 1 | |a Mnguni, Ayanda T |e verfasserin |4 aut | |
700 | 1 | |a Wasserman, Sean |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 22(2022), 1 vom: 20. Juni, Seite 559 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g day:20 |g month:06 |g pages:559 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-022-07519-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2022 |e 1 |b 20 |c 06 |h 559 |